Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Nov;39(11):2442–2445. doi: 10.1128/aac.39.11.2442

Proposed criteria for interpretation of susceptibilities of strains of Neisseria gonorrhoeae to ciprofloxacin, ofloxacin, enoxacin, lomefloxacin, and norfloxacin.

J S Knapp 1, J A Hale 1, S W Neal 1, K Wintersheid 1, R J Rice 1, W L Whittington 1
PMCID: PMC162962  PMID: 8585723

Abstract

The susceptibilities of 45 strains of Neisseria gonorrhoeae, including 25 strains susceptible to ciprofloxacin (MICs, < or = 0.06 microgram/ml) and 20 strains exhibiting decreased susceptibilities to ciprofloxacin (MICs, > or = 0.125 microgram/ml), to ciprofloxacin, ofloxacin, enoxacin, lomefloxacin, norfloxacin, and nalidixic acid were determined by agar dilution and disk diffusion. On the basis of theoretical calculations of predicted susceptibilities at which infections may fail therapy (supported by observed failures of infections to respond to the therapeutic doses of enoxacin and ciprofloxacin), the Centers for Disease Control and Prevention has adopted the following agar dilution breakpoints for interpretation of resistance to these agents: MICs of > or = 1.0 microgram of ciprofloxacin, enoxacin, and norfloxacin per ml and MICs of > or = 2.0 micrograms of ofloxacin and lomefloxacin per ml. The corresponding disk diffusion breakpoints for these agents were as follows: ciprofloxacin, < or = 29 mm; ofloxacin, < or = 24 mm; enoxacin, < or = 31 mm; lomefloxacin, < or = 26 mm; and norfloxacin, < or = 32 mm. The Centers for Disease Control and Prevention recommends two strains as interim quality control strains for susceptibility testing of ciprofloxacin and ofloxacin. These are N. gonorrhoeae CDC-10,328 (MIC of ciprofloxacin, 0.125 to 0.25 microgram/ml [inhibition zone diameter range, 30 to 34 mm]; MIC of ofloxacin, 0.5 microgram/ml [inhibition zone diameter range, 27 to 32 mm]) and N. gonorrhoeae CDC-10,329 (MIC of ciprofloxacin, 1.0 to 2.0 micrograms/ml [zone inhibition diameter range, 21 to 26 mm]; MIC of ofloxacin 2.0 micrograms/ml [inhibition zone diameter range, 18 to 21 mm]).

Full Text

The Full Text of this article is available as a PDF (235.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Birley H., McDonald P., Carey P., Fletcher J. High level ciprofloxacin resistance in Neisseria gonorrhoeae. Genitourin Med. 1994 Aug;70(4):292–293. doi: 10.1136/sti.70.4.292. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Clendennen T. E., Echeverria P., Saengeur S., Kees E. S., Boslego J. W., Wignall F. S. Antibiotic susceptibility survey of Neisseria gonorrhoeae in Thailand. Antimicrob Agents Chemother. 1992 Aug;36(8):1682–1687. doi: 10.1128/aac.36.8.1682. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Corkill J. E., Percival A., Lind M. Reduced uptake of ciprofloxacin in a resistant strain of Neisseria gonorrhoeae and transformation of resistance to other strains. J Antimicrob Chemother. 1991 Oct;28(4):601–604. doi: 10.1093/jac/28.4.601. [DOI] [PubMed] [Google Scholar]
  4. Fuchs P. C., Barry A. L., Baker C., Murray P. R., Washington J. A., 2nd Proposed interpretive criteria and quality control parameters for testing in vitro susceptibility of Neisseria gonorrhoeae to ciprofloxacin. J Clin Microbiol. 1991 Oct;29(10):2111–2114. doi: 10.1128/jcm.29.10.2111-2114.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fuchs P. C., Barry A. L., Baker C., Murray P. R., Washington J. A. Proposed interpretive criteria and quality control parameters for ofloxacin susceptibility testing of Neisseria gonorrhoeae. J Clin Microbiol. 1992 Apr;30(4):1024–1026. doi: 10.1128/jcm.30.4.1024-1026.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Gransden W. R., Warren C. A., Phillips I., Hodges M., Barlow D. Decreased susceptibility of Neisseria gonorrhoeae to ciprofloxacin. Lancet. 1990 Jan 6;335(8680):51–51. doi: 10.1016/0140-6736(90)90177-7. [DOI] [PubMed] [Google Scholar]
  7. Jaffe H. W., Schroeter A. L., Reynolds G. H., Zaidi A. A., Martin J. E., Jr, Thayer J. D. Pharmacokinetic determinants of penicillin cure of gonococcal urethritis. Antimicrob Agents Chemother. 1979 Apr;15(4):587–591. doi: 10.1128/aac.15.4.587. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Jephcott A. E., Turner A. Ciprofloxacin resistance in gonococci. Lancet. 1990 Jan 20;335(8682):165–165. doi: 10.1016/0140-6736(90)90035-4. [DOI] [PubMed] [Google Scholar]
  9. Knapp J. S. Laboratory methods for the detection and phenotypic characterization of Neisseria gonorrhoeae strains resistant to antimicrobial agents. Sex Transm Dis. 1988 Oct-Dec;15(4):225–233. doi: 10.1097/00007435-198810000-00009. [DOI] [PubMed] [Google Scholar]
  10. Knapp J. S., Ohye R., Neal S. W., Parekh M. C., Higa H., Rice R. J. Emerging in vitro resistance to quinolones in penicillinase-producing Neisseria gonorrhoeae strains in Hawaii. Antimicrob Agents Chemother. 1994 Sep;38(9):2200–2203. doi: 10.1128/aac.38.9.2200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Knapp J. S., Washington J. A., Doyle L. J., Neal S. W., Parekh M. C., Rice R. J. Persistence of Neisseria gonorrhoeae strains with decreased susceptibilities to ciprofloxacin and ofloxacin in Cleveland, Ohio, from 1992 through 1993. Antimicrob Agents Chemother. 1994 Sep;38(9):2194–2196. doi: 10.1128/aac.38.9.2194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Putnam S. D., Lavin B. S., Stone J. R., Oldfield E. C., 3rd, Hooper D. G. Evaluation of the standardized disk diffusion and agar dilution antibiotic susceptibility test methods by using strains of Neisseria gonorrhoeae from the United States and Southeast Asia. J Clin Microbiol. 1992 Apr;30(4):974–980. doi: 10.1128/jcm.30.4.974-980.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Rice R. J., Knapp J. S. Antimicrobial susceptibilities of Neisseria gonorrhoeae strains representing five distinct resistance phenotypes. Antimicrob Agents Chemother. 1994 Jan;38(1):155–158. doi: 10.1128/aac.38.1.155. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Tapsall J. W., Shultz T. R., Lovett R., Munro R. Failure of 500 mg ciprofloxacin therapy in male urethral gonorrhoea. Med J Aust. 1992 Jan 20;156(2):143–143. doi: 10.5694/j.1326-5377.1992.tb126457.x. [DOI] [PubMed] [Google Scholar]
  15. Turner A., Jephcott A. E., Gough K. R. Laboratory detection of ciprofloxacin resistant Neisseria gonorrhoeae. J Clin Pathol. 1991 Feb;44(2):169–170. doi: 10.1136/jcp.44.2.169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. van der Willigen A. H., van der Hoek J. C., Wagenvoort J. H., van Vliet H. J., van Klingeren B., Schalla W. O., Knapp J. S., van Joost T., Michel M. F., Stolz E. Comparative double-blind study of 200- and 400-mg enoxacin given orally in the treatment of acute uncomplicated urethral gonorrhea in males. Antimicrob Agents Chemother. 1987 Apr;31(4):535–538. doi: 10.1128/aac.31.4.535. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES